Increase in prophylaxis of glucocorticoid-induced osteoporosis by pharmacist feedback: a randomised controlled trial

C. Klop, F. de Vries, T. Vinks, M.J. Kooij, T.P. van Staa, J.W.J. Bijlsma, A.C.G. Egberts, M.L. Bouvy

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

The aim of this study was to determine whether feedback by pharmacists to prescribers of patients eligible for glucocorticoid-induced osteoporosis prophylaxis would stimulate the prescribing of osteoporosis prophylaxis. The intervention did not significantly increase the prescribing of bisphosphonates in the total study population, but a significant increase was seen in men and in the elderly. However, the proportion of bisphosphonate-treated patients remained low. The aim of this study was to determine whether feedback by pharmacists to prescribers of patients eligible for glucocorticoid-induced osteoporosis prophylaxis (GIOP) would stimulate the implementation of the Dutch GIOP guideline. This randomised controlled trial included 695 patients who were dispensed a parts per thousand yen675 mg prednisone equivalents without a concomitant bisphosphonate prescription within 6 months before baseline. Pharmacists were asked to contact the physicians of GIOP-eligible patients in the intervention group to suggest osteoporosis prophylaxis. The primary endpoint was a bisphosphonate prescription. Secondary endpoints were a prescription of calcium supplements, vitamin D or any prophylactic osteoporosis drug (bisphosphonate, calcium supplements, vitamin D). The group assigned to the intervention was slightly younger than the control group (68.7 +/- 15.4 vs. 65.9 +/- 16.9 years, p = 0.02) and used hydrocortisone more often (7.0 % vs. 3.1 %, p = 0.02). Within 6 months, the intervention did not significantly increase the prescribing of bisphosphonates (11.4 % after intervention vs. 8.0 % for controls; hazard ratio [HR] 1.47, 95 % confidence interval [CI] 0.91-2.39). However, subgroup analyses showed a significant increase for the primary endpoint in men (12.8 % vs. 5.1 %, HR 2.53, 95 % CI 1.11-5.74) and patients a parts per thousand yen70 years (13.4 % vs. 4.9 %, HR 2.88, 95 % CI 1.33-6.23). The prescribing of calcium and vitamin D was not significantly altered. This study showed that active identification of patients eligible for GIOP by pharmacists did not significantly increase the prescribing of bisphosphonates in the total study population, but there was an increase in men and the elderly. However, the proportion of GIOP-treated patients remained low.
Original languageEnglish
Pages (from-to)385-392
Number of pages8
JournalOsteoporosis International
Volume25
Issue number1
DOIs
Publication statusPublished - 1 Jan 2014

Keywords

  • Glucocorticoid-induced osteoporosis
  • Intervention
  • Pharmacist
  • Physician
  • CORTICOSTEROID-INDUCED OSTEOPOROSIS
  • PRACTICE PATTERNS
  • FRACTURE RISK
  • PREVENTION
  • MANAGEMENT
  • INTERVENTION
  • RISEDRONATE
  • MULTICENTER
  • MEDICATION
  • TRENDS

Cite this

Klop, C., de Vries, F., Vinks, T., Kooij, M. J., van Staa, T. P., Bijlsma, J. W. J., Egberts, A. C. G., & Bouvy, M. L. (2014). Increase in prophylaxis of glucocorticoid-induced osteoporosis by pharmacist feedback: a randomised controlled trial. Osteoporosis International, 25(1), 385-392. https://doi.org/10.1007/s00198-013-2562-8